Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anlotinib with or without iodine-125 seed implantation for recurrent or metastatic advanced cervical cancer
ChiCTR1900020906Phase 2Not yet recruiting
- Sponsor
- The First People's Hospital of Yueyang
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in Cervical Cancer (CC) (3 arms), sponsored by The First People's Hospital of Yueyang. Primary endpoints: objective response rate, local control rate and 1 more. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900020906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020906.